Mayo Clinic Cancer Center

Phase	Trial	Trial Status	Site Status	Drug	NCT#
1/2	Phase 1/2 Study of MRTX1719 in Solid Tumors With MTAP Deletion	Recruiting	Active	MRTX1719	NCT05245500
5	Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors	Recruiting	Available	Bezuclastinib	NCT06948955
3	A Study of IDRX-42 (GSK6042981) Versus (vs) Sunitinib in Participants With Gastrointestinal Stromal Tumors After Imatinib Therapy (StrateGIST 3)	Recruiting	Active	IDRX-42	NCT07218926
1	A Study of Ziftomenib, an Oral Menin Inhibitor, in Combination With Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)	Recruiting	Active	Ziftomenib + Imatinib	NCT06655246
3	(VOYAGER) Study of Avapritinib vs Regorafenib in Patients With Locally Advanced Unresectable or Metastatic GIST	Active, not recruiting	Active	Avapritinib or Regorafenib	NCT03465722
1	A Study of XmAb®18087 in Subjects With NET and GIST	Active, not recruiting	Closed	XmAb18087	NCT03411915